Lidocaine attenuates lipopolysaccharide-induced inflammatory responses in microglia

Journal of Surgical Research

Volumn 192, Issue 1, 2014, Pages 150-162

  Yuan, Tong ^a   Li, Zhiwen ^a   Li, Xinbai ^a   Yu, Gaoqi ^a   Wang, Na ^a   Yang, Xige ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Inflammation; Lidocaine; Lipopolysaccharides; Microglia; NF kappa B; p38 MAPK

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIDOCAINE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIOXIDANT; AUTACOID; CCL2 PROTEIN, RAT; ENZYME INHIBITOR; I KAPPA B; IMIDAZOLE DERIVATIVE; LOCAL ANESTHETIC AGENT; NF-KAPPAB INHIBITOR ALPHA; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; SMALL INTERFERING RNA; THIOCARBAMIC ACID DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PRIMARY CELL CULTURE; SPRAGUE DAWLEY RAT;

ANESTHETICS, LOCAL; ANIMALS; ANTIOXIDANTS; CHEMOKINE CCL2; ENZYME INHIBITORS; I-KAPPA B PROTEINS; IMIDAZOLES; INFLAMMATION MEDIATORS; LIDOCAINE; LIPOPOLYSACCHARIDES; MICROGLIA; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; PYRIDINES; PYRROLIDINES; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; THIOCARBAMATES; TRANSCRIPTION FACTOR RELA;

EID: 84921808623     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.05.023     Document Type: Article

References (45)

1. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002;40:133.
2. Kaur G, Han SJ, Yang I, Crane C. Microglia and central nervous system immunity. Neurosurg Clin N Am 2010;21:43.
3. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol 2010;119:89.
4. Takeuchi H, Jin S, Wang J, et al. Tumor necrosis factor-αlpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006;281:21362.
5. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal 2009;11:2151.
6. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315.
7. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918.
8. Tasi WC, Petersen-Jones SM, Huang PY, Lin CT. The neuroprotective effects of lidocaine and methylprednisolone in a rat model of retinal ischemia-reperfusion injury. J Vet Med Sci 2012;74:307.
9. Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiol 2000;93:858.
10. Caracas HCPM, Maciel JVB, de Souza MMG, et al. The use of lidocaine as an anti-inflammatory substance: a systematic review. J Dent 2009;37:93.
11. Kaczmarek DJ, Herzog C, Larmann J, et al. Lidocaine protects from myocardial damage due to ischemia and reperfusion in mice by its antiapoptotic effects. Anesthesiol 2009;110:1041.
12. Lan W, Harmon D, Wang J, Ghori K, Shorten G, Redmond P. The effect of lidocaine on in vitro neutrophil and endothelial adhesion molecule expression induced by plasma obtained during tourniquet-induced ischaemia and reperfusion. Eur J Anaesthesiol 2004;21:892.
13. Gallos G, Jones DR, Nasr SH, et al. Local anesthetics reduce mortality and protect against renal and hepatic dysfunction in murine septic peritonitis. Anesthesiol 2004;101:902.
14. Jeong HJ, Lin D, Li L, Zuo Z. Delayed treatment with lidocaine reduces mouse microglial cell injury and cytokine production after stimulation with lipopolysaccharide and interferon gamma. Anesth Analg 2012;114:856.
15. Feng G, Liu S, Wang G-L, et al. Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting NF-κB activation. Pharmacol 2007;81:32.
16. Lee PY, Tsai PS, Huang YH, et al. Inhibition of toll-like receptor-4, nuclear factor-κB and mitogen-activated protein kinase by lignocaine may involve voltage-sensitive sodium channels. Clin Exp Pharmacol Physiol 2008;35:1052.
17. Su D, Gu Y, Wang Z, Wang X. Lidocaine attenuates proinflammatory cytokine production induced by extracellular adenosine triphosphate in cultured rat microglia. Anesth Analg 2010;111:768.
18. Wang HL, Zhang WH, Lei WF, Zhou CQ, Ye T. The inhibitory effect of lidocaine on the release of high mobility group box 1 in lipopolysaccharide-stimulated macrophages. Anesth Analg 2011;112:839.
19. Akundi RS, Candelario-Jalil E, Hess S, et al. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharideactivated primary rat microglia. Glia 2005;51:199.
20. Heese K, Fiebich BL, Bauer J, Otten U. NF-kappaB modulates lipopolysaccharide-induced microglial nerve growth factor expression. Glia 1998;22:401.
21. Zhan J, Zhang ZZ, Chen C, Chen K, Wang YL. Penehyclidine hydrochloride attenuates LPS-induced iNOS production by inhibiting p38 MAPK activation in endothelial cells. Mol Biol Rep 2012;39:1261.
22. Gao F, Ding B, Zhou L, Gao X, Guo H, Xu H. Magnesium sulfate provides neuroprotection in lipopolysaccharideactivated primary microglia by inhibiting NF-kappaB pathway. J Surg Res; 2013.
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101.
24. Zhu C, Xiong Z, Chen X, et al. Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-kappaB pathway in microglia cells. PloS one 2012; 7:e35125.
25. Park HY, Kim GY, Choi YH. Naringenin attenuates the release of pro-inflammatory mediators from lipopolysaccharidestimulated BV2 microglia by inactivating nuclear factorkappaB and inhibiting mitogen-activated protein kinases. Int J Mol Med 2012;30:204.
26. Park HY, Kim ND, Kim GY, et al. Inhibitory effects of diallyl disulfide on the production of inflammatory mediators and cytokines in lipopolysaccharide-activated BV2 microglia. Toxicol Appl Pharmacol 2012;262:177.
27. Huang YH, Yen JC, Lee JJ, Liao JF, Liaw WJ, Huang CJ. Suppressive effects of levobupivacaine on endotoxininduced microglial activation. J Surg Res 2013;184:989.
28. Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006;1:127.
29. Sugama S, Takenouchi T, Fujita M, et al. Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmune 2009;207:24.
30. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 2010;6:405.
31. Das S, Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res 2008;86:1199.
32. Gebicke-Haerter PJ. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 2001;54:47.
33. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193.
34. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003;17:13.
35. Wright JG, Christman JW. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003;2:211.
36. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008;263:591.
37. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab 2011;13:11.
38. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atheroscler 2002;160:91.
39. Nam N-H. Naturally occurring NF-B inhibitors. Mini Rev Med Chem 2006;6:945.
40. Luqman S, Pezzuto JM. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res 2010;24:949.
41. Lang A, Ben Horin S, Picard O, et al. Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor κB activation. Immunobiol 2010;215:304.
42. Pyo H, Jou I, Jung S, et al. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 1998;9:871.
43. Kim YJ, Hwang SY, Oh ES, et al. IL-1b, an immediate early protein secreted by activated microglia, induces iNOS/NO in C6 astrocytoma cells through p38 MAPK and NF-κB pathways. J Neurosci Res 2006;84:1037.
44. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010;58: 561.
45. Lemmen LJ, Klassen M, Duiser B. Intravenous lidocaine in the treatment of convulsions. JAMA 1978;239:2025.